JP2016526920A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526920A5
JP2016526920A5 JP2016533383A JP2016533383A JP2016526920A5 JP 2016526920 A5 JP2016526920 A5 JP 2016526920A5 JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016526920 A5 JP2016526920 A5 JP 2016526920A5
Authority
JP
Japan
Prior art keywords
replication competent
recombinant replication
competent retrovirus
retrovirus
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/049831 external-priority patent/WO2015021077A1/en
Publication of JP2016526920A publication Critical patent/JP2016526920A/ja
Publication of JP2016526920A5 publication Critical patent/JP2016526920A5/ja
Pending legal-status Critical Current

Links

JP2016533383A 2013-08-05 2014-08-05 最適化ａ−バルジを有する組換えベクター Pending JP2016526920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862433P 2013-08-05 2013-08-05
US61/862,433 2013-08-05
PCT/US2014/049831 WO2015021077A1 (en) 2013-08-05 2014-08-05 Recombinant vector with optimized a-bulge

Publications (2)

Publication Number Publication Date
JP2016526920A JP2016526920A (ja) 2016-09-08
JP2016526920A5 true JP2016526920A5 (enExample) 2017-09-14

Family

ID=52461883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533383A Pending JP2016526920A (ja) 2013-08-05 2014-08-05 最適化ａ−バルジを有する組換えベクター

Country Status (6)

Country Link
EP (1) EP3030659A4 (enExample)
JP (1) JP2016526920A (enExample)
CN (1) CN105579581A (enExample)
AU (1) AU2014306093A1 (enExample)
CA (1) CA2920049A1 (enExample)
WO (1) WO2015021077A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US12421524B2 (en) 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2021063366A1 (zh) * 2019-09-30 2021-04-08 中国科学院上海药物研究所 用于治疗动脉相关疾病的药物及其用途
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CA3176697A1 (en) * 2020-05-11 2021-11-18 Doughlas J. JOLLY Vectors and methods for in vivo transduction
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
AU2022212007A1 (en) 2021-01-29 2023-09-07 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US20050260568A1 (en) * 2004-04-30 2005-11-24 Min Gao Hepatitis C virus assays
DK2346995T3 (en) * 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US20110020814A1 (en) * 2009-06-05 2011-01-27 Ipierian, Inc. Methods and compositions for selection of stem cells
EP3546583A1 (en) * 2009-06-17 2019-10-02 Tocagen Inc. Producer cells for replication competent retroviral vectors

Similar Documents

Publication Publication Date Title
ES2779149T3 (es) Vector retroviral que tiene actividad inmunoestimuladora
EP2909324B1 (en) Retroviral vector with mini-promoter cassette
US11279949B2 (en) Recombinant vectors comprising 2A peptide
US11788101B2 (en) Genomic insulator elements and uses thereof
ES2911448T3 (es) Vectores combinados y métodos para el tratamiento del cáncer
JP2012503986A5 (enExample)
JP2015533510A5 (enExample)
JP2012503987A5 (enExample)
JP2024045608A (ja) 制御性ｒｎａを発現させるためのベクターシステム
JP2019503653A5 (enExample)
EP3030659A1 (en) Recombinant vector with optimized a-bulge
JP2023503858A (ja) ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用
Everson et al. Retroviral vector interactions with hematopoietic cells
TWI817997B (zh) 結合至階段特異性胚胎抗原4 (ssea4)之嵌合抗原受體及其用途
EP4249596A1 (en) New gene recombinant vaccinia virus and utilization thereof
Abaan et al. Gene therapy in human breast cancer
US11970708B2 (en) Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus
RU2697797C2 (ru) Генетическая конструкция для индукции пролиферации периферических моноцитов in vitro
JP2024526878A5 (enExample)
JP2024526878A (ja) 調節されたウイルス送達システムおよびその使用
CN1162643A (zh) 用于癌症治疗的分子嵌合体的制备方法及应用
HK40034205A (en) Chimeric antigen receptors that bind to ssea4 and uses thereof
WO2018073307A1 (en) Mlv-based gene therapy with mutated integrase coupled to peptides